Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

RAISE: Reteplase May Be Another Option for Stroke Thrombolysis

News Daily News

RAISE: Reteplase May Be Another Option for Stroke Thrombolysis

June 20, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

High Lp(a) Levels Harmful in Patients With and Without ASCVD

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

News Conference News ISC 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

February 08, 2024

Less Is More: Lp(a) Much More Atherogenic than LDL

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.